202 related articles for article (PubMed ID: 28800127)
21. MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis.
Nguyen HV; Vandenberg CJ; Robati MR; Ng AP; Cory S
Cell Death Differ; 2023 Apr; 30(4):1018-1032. PubMed ID: 36755068
[TBL] [Abstract][Full Text] [Related]
22. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
23. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
24. Evidence of mnt-myc antagonism revealed by mnt gene deletion.
Hurlin PJ; Zhou ZQ; Toyo-Oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
Cell Cycle; 2004 Feb; 3(2):97-9. PubMed ID: 14712062
[TBL] [Abstract][Full Text] [Related]
25. Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis.
Nakamura I; Roberts LR
Gastroenterology; 2011 Jul; 141(1):32-4. PubMed ID: 21620848
[No Abstract] [Full Text] [Related]
26. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
27. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
28. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.
Struntz NB; Chen A; Deutzmann A; Wilson RM; Stefan E; Evans HL; Ramirez MA; Liang T; Caballero F; Wildschut MHE; Neel DV; Freeman DB; Pop MS; McConkey M; Muller S; Curtin BH; Tseng H; Frombach KR; Butty VL; Levine SS; Feau C; Elmiligy S; Hong JA; Lewis TA; Vetere A; Clemons PA; Malstrom SE; Ebert BL; Lin CY; Felsher DW; Koehler AN
Cell Chem Biol; 2019 May; 26(5):711-723.e14. PubMed ID: 30880155
[TBL] [Abstract][Full Text] [Related]
29.
Mathsyaraja H; Freie B; Cheng PF; Babaeva E; Catchpole JT; Janssens D; Henikoff S; Eisenman RN
Genes Dev; 2019 Sep; 33(17-18):1252-1264. PubMed ID: 31395740
[TBL] [Abstract][Full Text] [Related]
30. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.
Hurlin PJ; Quéva C; Koskinen PJ; Steingrímsson E; Ayer DE; Copeland NG; Jenkins NA; Eisenman RN
EMBO J; 1995 Nov; 14(22):5646-59. PubMed ID: 8521822
[TBL] [Abstract][Full Text] [Related]
31. Mnt takes control as key regulator of the myc/max/mxd network.
Wahlström T; Henriksson M
Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
[TBL] [Abstract][Full Text] [Related]
32. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.
Hunter JE; Butterworth JA; Zhao B; Sellier H; Campbell KJ; Thomas HD; Bacon CM; Cockell SJ; Gewurz BE; Perkins ND
Oncogene; 2016 Jun; 35(26):3476-84. PubMed ID: 26522720
[TBL] [Abstract][Full Text] [Related]
33. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression.
Yang H; Li TW; Peng J; Tang X; Ko KS; Xia M; Aller MA
Gastroenterology; 2011 Jul; 141(1):378-88, 388.e1-4. PubMed ID: 21440549
[TBL] [Abstract][Full Text] [Related]
34. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
35. Reconstitution of an E box-binding Myc:Max complex with recombinant full-length proteins expressed in Escherichia coli.
Farina A; Faiola F; Martinez E
Protein Expr Purif; 2004 Apr; 34(2):215-22. PubMed ID: 15003254
[TBL] [Abstract][Full Text] [Related]
36. The Mad side of the Max network: antagonizing the function of Myc and more.
Rottmann S; Lüscher B
Curr Top Microbiol Immunol; 2006; 302():63-122. PubMed ID: 16620026
[TBL] [Abstract][Full Text] [Related]
37. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
38. Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators.
Sommer A; Bousset K; Kremmer E; Austen M; Lüscher B
J Biol Chem; 1998 Mar; 273(12):6632-42. PubMed ID: 9506959
[TBL] [Abstract][Full Text] [Related]
39. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
40. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
